Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.09
- Piotroski Score 3.00
- Grade Buy
- Symbol (COYA)
- Company Coya Therapeutics, Inc.
- Price $6.43
- Changes Percentage (5.76%)
- Change $0.35
- Day Low $6.15
- Day High $6.70
- Year High $10.69
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/18/2025
- Fiscal Year End N/A
- Average Stock Price Target $18.00
- High Stock Price Target $18.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.86
- Trailing P/E Ratio -8.36
- Forward P/E Ratio -8.36
- P/E Growth -8.36
- Net Income $-7,987,836
Income Statement
Quarterly
Annual
Latest News of COYA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Coya Therapeutics reported positive results from a Phase 2 trial of LD IL-2 for Alzheimer's at CTAD24. The study met primary and secondary endpoints, showing safety and efficacy. The q4wks dosing led ...
By Yahoo! Finance | 3 weeks ago -
Coya Therapeutics Shares Rise 9% After $10 Million Private Placement
Coya Therapeutics saw a surge in stock value after agreeing to sell 1.4 million shares in a private placement at $7.25 each. The company's shares rose by 9% to $9....
By MarketWatch | 1 month ago -
3 things I learned about longevity while visiting the Nicoya Peninsula of Costa Rica, one of the world's Blue Zones
Lessons on longevity from Costa Rica's Blue Zone emphasize simple, daily habits like fresh whole foods and regular exercise. Maintaining wellness in a modern world requires effort and intention, focus...
By Business Insider | 4 months ago
